Reviews

Cbdca s-1

Safety and efficacy of concurrent carboplatin or cetuximab plus This study compared the safety and efficacy of concurrent carboplatin (CBDCA) to cetuximab (Cmab) plus radiotherapy (RT) in patients ineligible for CDDP treatment. Methods We retrospectively analyzed LASCCHN patients who received CBDCA plus RT ( n = 29) or Cmab plus RT ( n = 18) due to ineligibility for CDDP treatment at two Japanese institutions between August 2006 and December 2015. Maneesriwongul, W. and Dixon, J.K. (2004) Instrument Translation The physical function after IPHC became worse compared to that before the IPHC. Fatigue during chemotherapy (CBDCA+S-1) was more pronounced than that during the IPHC. Nausea, vomiting, and diarrhea during the IPHC were prevalent than those of chemotherapy

P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)

P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)

Brunsbüttel Energie GmbH (BEG) Fährstraße 51, 25541 Brunsbüttel Brennwerte 2016 im Netzgebiet der Covestro Brunsbüttel Energie GmbH gemäß § 40 GasNZV Abs. 1 S. 1 Nr. 7

上記1)~4)以外は UICC TNM分類第8 版では病期分類の「該当せず」. 1.概要 B1・B2・B3のような気管支の分岐に合わせて、肺は右上葉がS1・S2・S3の、中葉がS4・S5、下葉 プラチナ製剤 (CDDP,CBDCA) + DTX / PTX / VNR / CPT-11. The anticancer drug carboplatin [Pt(cbdca-O,O′)(NH3)2] which contains the In contrast, the ring-closure rate of [Pt(en)(Me-Mal-O)(Met-Gly-S)] [k 1 = (1.37  Carboplatin (CBDCA), S-1 and concurrent thoracic radiotherapy Carboplatin (CBDCA), S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients with locally advanced non-small cell lung cancer (NSCLC): A phase II study. Clinical development of S-1 for non-small cell lung cancer: a For more than a decade, S-1 has been investigated aggressively against non-small cell lung cancer (NSCLC) in Japan. Recently, two randomized phase III trials of S-1 combined with cisplatin (CDDP) or carboplatin (CBDCA) compared with the standard platinum

Brunsbüttel Energie GmbH (BEG) Fährstraße 51, 25541 -

Conformational flexibility within the chelate rings of The exchange rate and the activation free energy (ΔG ‡) at 317 K were determined to be ca. 415 s-1 and 62 kJ mol-1, respectively. The CBDCA ligand appears to have a direct effect on the dynamics of the en ring. Conformational flexibility of the CBDCA ring is also discussed. Such dynamic processes within chelated platinum complexes could play Switch maintenance therapy with S-1 after induction therapy with Summary. Background Optimal maintenance therapy for lung squamous cell carcinoma (SCC) has not been established. The aim of this study was to evaluate the efficacy and safety of switch maintenance therapy with S-1, an oral fluoropyrimidine, after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in chemotherapy-naïve patients with advanced SCC.